Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851322 | 0.79 | FABP5 (0.43) | TSHRFABP5 | |
| SCHEMBL28430246 | 0.74 | FABP5 (0.45) | TSHRFABP5 | |
| SCHEMBL28430244 | 0.74 | FABP5 (0.45) | TSHRFABP5 | |
| SCHEMBL28896721 | 0.74 | FABP5 (0.45) | TSHRFABP5 | |
| SCHEMBL3660749 | 0.73 | DDB1 (0.48) | MAPK1ALDH1A1 | |
| SCHEMBL8141759 | 0.73 | DDB1 (0.48) | MAPK1ALDH1A1 | |
| SCHEMBL28200534 | 0.70 | — | — | |
| SCHEMBL3934353 | 0.69 | ARG1 (0.34) | AKR1C1 | |
| SCHEMBL24093870 | 0.69 | DDB1 (0.49) | MAPK1ALDH1A1 | |
| SCHEMBL10670488 | 0.69 | DDB1 (0.49) | MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333054-A1 | SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS | NIH - DEITR | 2016-11-17 | — | — | US | disclosed |
| US-9260484-B2 | Small molecule composite surfaces as inhibitors of protein-protein interactions | OHIO STATE INNOVATION FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140200186-A1 | SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS | NIH - DEITR | 2014-07-17 | — | — | US | disclosed |
| WO-2012174489-A2 | SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS | THE OHIO STATE UNIVERSITY (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200186-A1 | SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS | PAIP1, ECPAS, AIP | POLB 4058/4885MAPK1 2632/4885MAPT 3430/4885 |
| US-20160333054-A1 | SMALL MOLECULE COMPOSITE SURFACES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS | PAIP1, ECPAS, AIP | POLB 4058/4885MAPK1 2632/4885MAPT 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.